A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Exclusion Criteria

• •Presence of aquaporin-4-antibodies immunoglobin G (AQP4-IgG) in the serum
• •History of anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis
• •Any concomitant disease other than MOGAD that may require treatment with ISTs or oral corticosteroids (OCS) or intravenous (IV) corticosteroids at doses \> 20 milligrams (mg) prednisone equivalent per day for \>21 days during the study
• •Participants who are pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of satralizumab
• •Participants with active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection at baseline
• •Participants with evidence of latent or active tuberculosis (excluding patients receiving chemoprophylaxis for latent tuberculosis infection)
• •Participants with positive screening tests for hepatitis B and C
• •Receipt of live or live attenuated vaccine within 6 weeks prior to baseline
• •History of severe allergic reaction to a biologic agent